MOTS-c + NAD+ (Nicotinamide Adenine Dinucleotide) Peptide Stack

This innovative peptide stack integrates MOTS-c, a mitochondrial-derived peptide, with NAD+ (Nicotinamide Adenine Dinucleotide), a vital coenzyme. Both components are linked through their roles in mitochondrial function and energy metabolism, although direct interaction data between them remains sparse. Research has increasingly highlighted the importance of mitochondrial health in various physiological processes, including aging and metabolic regulation. The combination of these two compounds may offer insights into their collective impact on cellular energetics, potentially leading to breakthroughs in understanding metabolic disorders and age-related decline.

MOTS-c, a 16-amino-acid peptide derived from the mitochondrial 12S rRNA gene, was identified in 2015 by Lee et al. at the University of Southern California. This peptide has emerged as a significant metabolic regulator, primarily through its activation of AMP-activated protein kinase (AMPK). In preclinical studies, particularly in mouse models, MOTS-c has demonstrated the ability to mitigate diet-induced obesity and insulin resistance, enhance physical endurance, and counteract age-related metabolic decline. Notably, a modified analog, CB4211, has shown good tolerability in a Phase 1 human trial, although native MOTS-c has yet to undergo clinical trials in humans. Mechanistically, MOTS-c activates AMPK by disrupting the folate cycle, leading to increased levels of AICAR. This activation promotes energy efficiency by enhancing glucose uptake and fatty acid oxidation while reducing fat storage. Additionally, MOTS-c's translocation to the nucleus during stress conditions suggests its role in retrograde signaling, where it may upregulate antioxidant genes and modulate inflammatory pathways, including the NLRP3 inflammasome, thereby contributing to its potential healthspan benefits.

NAD+ serves as an essential coenzyme in cellular metabolism, functioning as a critical electron carrier in various metabolic pathways, including glycolysis, the tricarboxylic acid (TCA) cycle, and oxidative phosphorylation. Its levels decline significantly with age, approximately halving between the ages of 40 and 60, which has raised interest in its role in aging and metabolic health. Although NAD+ itself is not a peptide, it is frequently discussed alongside peptide research due to its vital functions and the potential therapeutic implications of its precursors, such as NMN and NR. Current research indicates that intravenous NAD+ infusions, commonly utilized in anti-aging clinics, offer nearly complete bioavailability, yet their plasma half-life is relatively short, approximately 30 minutes. Mechanistically, NAD+ acts as a substrate for various enzymes, including sirtuins, PARPs, and CD38, all of which play critical roles in gene regulation, DNA repair, and cellular signaling. The age-related decline in NAD+ is attributed to increased CD38 expression and decreased NAMPT activity, highlighting the potential for NAD+ replenishment strategies in clinical settings.